FORT WORTH, Texas, Aug. 18 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM) announced today that its new international distributor, Spiramed (Pty) Ltd, exhibited its advanced wound care collagen product, CellerateRX® last weekend at the DFWG (Diabetic Foot Working Group) congress in Cape Town and has already planned exhibitions at two additional upcoming conferences. This second meeting of the DFWG congress was attended by over 120 diabetic foot specialists. Spiramed will also be exhibiting CellerateRX® at the UBUNTU International Conference-A Global Wound Healing Initiative September 5-8. This conference is hosted by South Africa and endorsed by the Wound Healing Association of Southern Africa. Other supporting organizations include the World Alliance of Wound and Lymphedema Care, World Health Organization, The Lindsay Leg Club Foundation, and Wound International. The programme is focused on assessing the scope of wound care issues in economically challenged countries and proposing strategies and solutions in the area of wound care. They will also be showcasing CellerateRX® at the VASSA 2010 Congress (Vascular Society of Southern Africa) in October.
"We are excited about CellerateRX®'s introduction to the South African market," stated Cathy Bradshaw, President of Wound Care Innovations, a subsidiary of Wound Management Technologies. "According to the World Diabetes Foundation, the estimated number of people with diabetes in South Africa is approximately 840,000, with a projected increase to 1.3 million in the next few years. Statistics show that around 15% of these people will develop a diabetic foot ulcer at some point in their lives. We believe that CellerateRX® can have an enormous impact in the management of the related wounds."